List of Excipients in Branded Drug FLUDEOXYGLUCOSE F18

« Back to Dashboard

Generic Drugs Containing FLUDEOXYGLUCOSE F18

Company	Ingredient	NDC	Excipient
Biomedical Research Foundation of Northwest Louisiana	fludeoxyglucose f-18	24562-003	ALCOHOL
Biomedical Research Foundation of Northwest Louisiana	fludeoxyglucose f-18	24562-003	PHOSPHORIC ACID
Biomedical Research Foundation of Northwest Louisiana	fludeoxyglucose f-18	24562-003	SODIUM CHLORIDE
Wisconsin Medical Cyclotron LLC	fludeoxyglucose f-18	44338-001	ALCOHOL
Wisconsin Medical Cyclotron LLC	fludeoxyglucose f-18	44338-001	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in FLUDEOXYGLUCOSE F18?

# Of NDCs	Excipient
3	ALCOHOL
1	PHOSPHORIC ACID
3	SODIUM CHLORIDE
2	SODIUM CITRATE

Fludeoxyglucose F18 Excipient Strategy and Commercial Opportunities

Last updated: September 28, 2026

Fludeoxyglucose F18, commonly called FDG F18 or 18F-FDG, is a short-lived PET radiopharmaceutical used primarily for oncology imaging and, in some indications, neurology and cardiology. Its excipient strategy is constrained by a 109.7-minute physical half-life, intravenous administration, low injected volumes, rapid release, and strict radiochemical and microbiological controls. The strongest commercial opportunities are not conventional reformulation plays. They are in sterile excipient systems, synthesis and dispensing consumables, radiochemical stabilization, container-closure systems, quality control, automation, and regional manufacturing infrastructure.

What is the regulatory status of fludeoxyglucose F18?

Fludeoxyglucose F18 injection is an FDA-approved diagnostic PET drug. It is administered intravenously and is used to assess abnormal glucose metabolism, including evaluation of malignancies and certain neurological and cardiac conditions. PET drugs are subject to the FDA’s PET drug current good manufacturing practice framework in 21 C.F.R. Part 212, as well as applicable drug product, sterility, identity, potency, and quality requirements.[1]

FDG F18 is not a biologic and does not create a biosimilar pathway. Biosimilar risk is therefore not applicable. Competition generally arises from:

• Multiple approved or authorized PET drug manufacturers
• Hospital and academic cyclotron production
• Centralized radiopharmacy networks
• Contract manufacturing and dose-delivery providers
• Regional PET drug distributors
• Potential abbreviated or alternative regulatory pathways for comparable products

Because the isotope decays rapidly, commercial competition depends heavily on local or regional production capacity. A manufacturer that lacks cyclotron access, radiochemistry capability, or reliable same-day distribution has limited ability to compete regardless of formulation quality.

What excipients are used in fludeoxyglucose F18 injection?

There is no single universal FDG F18 excipient formula. Commercial formulations generally use a sterile aqueous vehicle with sodium chloride and, depending on the product and manufacturing process, pH-adjusting or buffering components. Product-specific labels and compendial specifications control the final composition.

Typical excipient categories include:

Excipient category	Examples	Commercial function
Tonicity agent	Sodium chloride	Supports intravenous tolerability and isotonicity
Buffer or pH adjuster	Sodium citrate, hydrochloric acid, sodium hydroxide	Controls pH during synthesis, purification, and storage
Vehicle	Water for Injection	Provides the injectable medium
Process-related components	Ethanol or other synthesis solvents, where applicable	Used during production but controlled as residual impurities
Chelation or scavenging components	Product-specific and uncommon	May address trace-metal or radiolytic degradation risks
Preservatives	Generally avoided	Limits toxicity, compatibility, and regulatory complexity

The finished product is typically a low-volume, sterile, aqueous injection without a conventional antimicrobial preservative. The product must meet requirements for radionuclide identity, radiochemical purity, chemical purity, pH, sterility, endotoxins, residual solvents, and activity concentration.[2]

An excipient used in the synthesis process is not automatically an excipient in the finished drug product. Residual solvents, precursor-derived impurities, phase-transfer catalysts, and synthesis reagents must be controlled under the applicable specifications even when they are absent from the final formulation.

How does FDG F18’s half-life affect excipient selection?

The 109.7-minute half-life changes the formulation economics. Conventional long-term stability programs are less important than short-window stability through release, transport, administration, and dose completion.

A useful commercial target is stability over the operational period needed for:

1. Automated or manual dispensing
2. Quality-control testing
3. Shipment to imaging sites
4. Patient administration
5. Residual-dose management

The principal formulation risks are radiolysis, pH drift, adsorption to container surfaces, metal contamination, particulate formation, and loss of radiochemical purity. Excipients must not materially increase any of these risks.

The short half-life also reduces the value of strategies that depend on multi-month shelf life. A formulation improvement that adds one year of chemical stability has limited value if radioactive activity falls by half every 109.7 minutes. Commercial value instead comes from:

• Lower radiochemical degradation during the same-day use period
• Longer validated transportation windows
• Fewer rejected doses
• Higher available activity at the point of administration
• Greater production-to-injection flexibility
• Lower operator intervention
• Better compatibility with automated dispensing systems

What is the optimal excipient strategy for FDG F18?

The preferred strategy is a minimal-excipient, low-risk formulation that protects radiochemical quality without complicating release testing or intravenous administration.

1. Use a simple isotonic aqueous platform

Sodium chloride and Water for Injection are commercially established and operationally simple. A basic vehicle reduces formulation risk, minimizes extractables and leachables concerns, and supports compatibility with standard PET injection systems.

2. Control pH without over-buffering

pH adjustment is necessary because synthesis and purification can introduce acidic or basic residues. A weak buffer or controlled acid-base adjustment may improve reproducibility, but excessive buffer capacity can increase ionic load and complicate downstream purification.

The target is a formulation that maintains product quality during the validated use period while avoiding unnecessary buffer components. Product-specific data must establish the relationship among pH, radiochemical purity, residual solvent levels, and radiolysis.

3. Avoid unnecessary preservatives

Preservatives have limited commercial value in a product intended for rapid use. They may create toxicity, compatibility, labeling, and regulatory burdens. Aseptic processing, sterile filtration where appropriate, validated container closure, and controlled dispensing are generally more attractive than preservation chemistry.

4. Evaluate radiolysis controls carefully

Radiolysis is a central formulation issue for radiopharmaceuticals. Antioxidant or radical-scavenging excipients may improve radiochemical stability, but they can also introduce new impurities, complicate analytical methods, or create toxicological and regulatory questions.

A commercially viable stabilizer must demonstrate:

• Improved radiochemical purity during the intended use period
• No adverse effect on biodistribution
• No clinically meaningful pharmacological activity
• Acceptable intravenous safety
• Validated assay performance
• Compatibility with automated synthesis and dispensing equipment
• Limited impact on residual solvent and impurity profiles

5. Treat metals and container interactions as formulation variables

Trace metals can affect radiochemical reactions and degradation. Excipient suppliers that offer low-metal-grade raw materials, certified Water for Injection, low-extractable tubing, and compatible vial systems may create more value than suppliers offering novel formulation ingredients.

For FDG F18, container-closure performance is part of the formulation strategy. Vials, syringes, septa, needles, transfer sets, and tubing must be evaluated for adsorption, extractables, leachables, radiation exposure, and dose recovery.

What formulation patents protect fludeoxyglucose F18 products?

The core FDG active ingredient is old and widely used. Commercial patent value is therefore more likely to arise from a specific formulation, manufacturing process, kit, container system, or automated delivery platform than from FDG itself.

Potentially protectable areas include:

Technology area	Patent opportunity	Relative commercial value
Novel excipient combination	Stabilized FDG formulation with improved radiochemical purity	Moderate
Radiolysis control	Antioxidant or scavenger system with validated safety and performance	Moderate
Automated synthesis	Cassette, reactor, purification, or process-control architecture	High
Sterile dispensing	Dose preparation and transfer system that reduces activity loss	High
Container closure	Low-adsorption, low-extractables vial or syringe configuration	Moderate
Logistics	Packaging or temperature-control system extending operational delivery windows	Moderate
Quality control	Rapid release testing and activity-correction systems	Moderate
Method of use	New clinical interpretation or imaging protocol	Variable
FDG molecule itself	Basic composition-of-matter protection	Limited

A patent directed only to the use of sodium chloride or Water for Injection is unlikely to create strong differentiation. A stronger claim would connect the excipient system to a measurable technical result, such as reduced radiochemical degradation, improved delivered activity, lower adsorption, or a longer validated hold time.

What is the Orange Book status of fludeoxyglucose F18?

Orange Book analysis must be performed by product, sponsor, proprietary name, and NDA. FDG F18 products do not share one universal patent listing or one common exclusivity date. Product-specific formulations, manufacturing methods, and use patents may be absent, expired, or separately listed.

The principal Orange Book questions are:

• Which FDG F18 product is being evaluated?
• Does its NDA contain listed patents?
• Are any listed patents directed to formulation, method of use, or manufacturing?
• Are the patents expired, delisted, or subject to a certification?
• Does the proposed competing product rely on the same reference product?
• Is an ANDA, 505(b)(2) application, or another pathway legally available?

A Paragraph IV challenge is more plausible for a product with listed formulation or method-of-use patents than for a basic FDG formulation. The short commercial life of each manufactured dose can also reduce the value of prolonged patent litigation. Litigation economics depend on manufacturing scale, hospital contracts, geographic coverage, and the competitive value of the underlying PET drug network.

When does FDG F18 lose exclusivity?

FDG F18 does not have one market-wide exclusivity-loss date. The active ingredient is old, and many market participants already operate in the field. Commercial exclusivity is fragmented across:

• Product-specific regulatory approvals
• Patent rights
• Local manufacturing licenses
• Hospital and health-system contracts
• Cyclotron access
• Radiopharmacy distribution infrastructure
• Reimbursement and coverage arrangements

Any remaining exclusivity must be analyzed at the individual product and jurisdiction level. Basic FDG formulation competition is already established in the United States and other major markets. The more relevant commercial barrier is often operational capability rather than legal exclusivity.

What manufacturing and intellectual-property barriers affect FDG F18?

The main barriers are technical and logistical.

Cyclotron and target systems

Production requires a suitable cyclotron and an enriched oxygen-18 water target. Oxygen-18 water is expensive and must be recovered efficiently. Target reliability, isotope recovery, and maintenance affect cost of goods.

Radiochemistry platform

The manufacturer needs validated radiosynthesis equipment, precursor supply, purification capability, sterile processing, and qualified personnel. Automated synthesis systems can reduce variability and radiation exposure but require validated cassettes, software, and maintenance.

Quality control

Release testing must be rapid enough to preserve clinical utility. Testing commonly addresses appearance, pH, radionuclide identity and half-life, radiochemical purity, chemical purity, residual solvents, endotoxins, and sterility controls. Sterility testing may be completed post-release under applicable procedures because the product’s useful life is short, but the regulatory framework requires validated controls.[1,2]

Distribution

FDG F18 is a time-sensitive product. Geographic coverage depends on production density, route reliability, dose scheduling, and the ability to manage cancellations. A formulation that improves stability by even a limited number of hours can have commercial value if it expands the delivery radius or reduces discarded doses.

Which companies are positioned to commercialize FDG F18 excipient technologies?

Commercial opportunities exist across several supplier categories:

• Radiopharmaceutical manufacturers
• Hospital and academic PET centers
• Contract development and manufacturing organizations
• Cyclotron manufacturers
• Automated synthesis and dispensing equipment companies
• Sterile vial, syringe, tubing, and septum suppliers
• Specialty excipient manufacturers
• Radiopharmacy software and logistics providers
• Quality-control instrument companies

The strongest customer segment is not necessarily the largest pharmaceutical company. Regional radiopharmacies and hospital networks may pay for solutions that reduce failed batches, extend delivery radius, simplify release testing, and improve dose recovery.

Potential deal structures include:

Deal type	Appropriate asset
Supply agreement	Low-metal excipients, sterile components, or validated container systems
Technology license	Stabilizer formulation, synthesis cassette, or dispensing platform
Contract manufacturing	Regional FDG production under a validated process
Equipment placement	Automated synthesis and dose-dispensing systems
Co-development	Formulation and container-closure validation
Data or software license	Scheduling, activity decay, route optimization, and dose reconciliation

How strong is the patent estate for FDG F18 excipient technology?

The patent estate for the basic FDG injection is likely weaker than the patent estate for newer radiopharmaceuticals. The strongest defensible positions are narrow and implementation-focused.

Patent strength is highest when a claimed formulation:

• Produces a reproducible technical benefit
• Uses a defined concentration range
• Demonstrates superiority over a conventional saline formulation
• Has data across activity concentrations and production sites
• Is linked to a validated manufacturing or dispensing process
• Avoids dependence on a single unproven mechanism
• Supports regulatory filing and commercial supply

Patent strength is lower when claims cover a generic sterile aqueous formulation, conventional tonicity adjustment, routine pH control, or an excipient selected from a broad list without comparative performance data.

Freedom-to-operate risk is usually more important for automated synthesis equipment, software, cassettes, and proprietary container systems than for standard saline-based excipients.

What commercial opportunities are most attractive?

The highest-value opportunities are operationally linked to dose delivery.

High-priority opportunities

1. Low-adsorption syringes, vials, and tubing that improve recovered activity.
2. Validated stabilizer systems that reduce radiochemical degradation during same-day use.
3. Automated dose dispensing with decay correction and activity reconciliation.
4. Lower-cost oxygen-18 water recovery and recycling.
5. Modular sterile synthesis cassettes with consistent impurity control.
6. Regional manufacturing systems that reduce transport distance.
7. Predictive scheduling tools that reduce unused doses.
8. Rapid quality-control platforms that shorten release time.
9. Integrated packaging for radiation protection and temperature control.
10. Contract manufacturing services for hospitals without full radiochemistry infrastructure.

Lower-priority opportunities

Conventional excipient substitution without a demonstrated performance benefit is less attractive. A new buffer, preservative, or tonicity agent must overcome established supply chains and the regulatory preference for simple, well-characterized formulations.

How does FDG F18 compare with newer PET radiopharmaceuticals?

FDG F18 is a high-volume, mature PET product with broad clinical familiarity and established manufacturing practices. Newer agents may have stronger patent protection and higher per-dose pricing, but they often face narrower indications, smaller patient populations, and more complex reimbursement conditions.

Factor	FDG F18	Newer targeted PET agents
Active-ingredient patent strength	Generally limited	Often stronger
Manufacturing maturity	High	Variable
Distribution sensitivity	Very high	High
Formulation complexity	Usually low	Often higher
Clinical demand	Broad	Indication-specific
Excipient differentiation	Limited but practical	Potentially greater
Main competitive barrier	Production and logistics	IP, clinical adoption, and manufacturing

FDG F18 is therefore better suited to cost-reduction and infrastructure investments than to premium formulation branding.

Key Takeaways

• FDG F18 uses a simple sterile aqueous formulation, commonly involving sodium chloride, Water for Injection, and product-specific pH adjustment.
• The 109.7-minute half-life makes same-day radiochemical stability more valuable than long-term shelf life.
• Preservative-free, low-excipient formulations are generally the most commercially practical.
• Excipient patents are strongest when tied to measurable improvements in radiochemical purity, activity recovery, delivery radius, or dispensing efficiency.
• The core FDG molecule offers limited new composition-of-matter opportunity.
• Manufacturing, cyclotron access, oxygen-18 recovery, automated synthesis, quality control, and distribution are the main competitive barriers.
• Biosimilar risk does not apply because FDG F18 is a small-molecule radiopharmaceutical, not a biologic.
• Orange Book and Paragraph IV analysis must be conducted by individual product and NDA.
• The most attractive commercial opportunities are in stabilizers, container systems, synthesis cassettes, automated dispensing, logistics, and radiopharmacy infrastructure.

FAQs

Is sodium chloride the only important excipient in FDG F18 injection?

No. Sodium chloride is common, but product-specific formulations may include pH-adjusting or buffering components. The final composition depends on the manufacturer’s synthesis, purification, and release specifications.

Can antioxidants be added to fludeoxyglucose F18?

Potentially, but the antioxidant must demonstrate improved radiochemical stability without affecting safety, biodistribution, impurity control, automated synthesis, or regulatory acceptance.

Are FDG F18 formulations eligible for generic-drug competition?

Competition may be possible through product-specific regulatory pathways, but the applicable route depends on the reference product, formulation, manufacturing process, and FDA requirements. The commercial challenge is often local production and distribution rather than the active ingredient.

What is the most valuable patent opportunity in FDG F18?

The strongest opportunities are usually in automated synthesis, dose dispensing, container closure, radiolysis control, and logistics systems that produce measurable reductions in waste or activity loss.

Can a longer FDG F18 shelf life create a major commercial advantage?

A longer operational hold time can expand distribution and reduce discarded doses. However, the isotope’s physical half-life limits the value of conventional long-term shelf-life improvements.

References

1. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for PET drugs, 21 C.F.R. Part 212. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-212

2. U.S. Pharmacopeia. (2024). General Chapter <823>: Positron emission tomography drugs for compounding, investigational, and research uses. United States Pharmacopeial Convention.

3. U.S. Food and Drug Administration. (2018). PET drugs: Current good manufacturing practice; small entity compliance guide. https://www.fda.gov

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. International Atomic Energy Agency. (2014). Cyclotron produced radionuclides: Guidelines for setting up a facility. IAEA.